Qiagen N.V. $QGEN Shares Sold by Capital International Inc. CA

Capital International Inc. CA lessened its stake in shares of Qiagen N.V. (NYSE:QGEN) by 6.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 474,081 shares of the company’s stock after selling 32,380 shares during the quarter. Capital International Inc. CA’s holdings in Qiagen were worth $21,319,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Massachusetts Financial Services Co. MA lifted its stake in shares of Qiagen by 1.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after purchasing an additional 264,921 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Qiagen by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock worth $433,871,000 after purchasing an additional 118,135 shares in the last quarter. Amundi lifted its stake in shares of Qiagen by 4.4% during the third quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after purchasing an additional 181,509 shares in the last quarter. Boston Partners acquired a new position in shares of Qiagen during the third quarter worth about $179,450,000. Finally, Norges Bank acquired a new position in shares of Qiagen during the fourth quarter worth about $166,500,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Up 0.0%

NYSE:QGEN opened at $36.69 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. Qiagen N.V. has a one year low of $32.53 and a one year high of $57.81. The business’s 50-day simple moving average is $37.33 and its 200 day simple moving average is $44.38. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 3.65 and a beta of 0.66.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business had revenue of $492.32 million for the quarter, compared to analysts’ expectations of $496.15 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. As a group, sell-side analysts predict that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be paid a $0.35 dividend. This represents a dividend yield of 104.0%. This is a positive change from Qiagen’s previous annual dividend of $0.26. The ex-dividend date is Tuesday, July 7th. Qiagen’s payout ratio is presently 13.61%.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of recent research reports. Citigroup restated a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. UBS Group set a $52.00 price target on Qiagen in a research note on Monday, February 9th. Robert W. Baird set a $43.00 price target on Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and a consensus price target of $44.98.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.